High aldehyde dehydrogenase (ALDH) activity characterizes a subpopulation of cells with cancer stem cell (CSC) properties in several malignancies. 
INTRODUCTION
Cervical cancer is the second most commonly diagnosed cancer and ranks second only to breast cancer as the leading cause of cancer death in women in developing countries [1] . Based on the GLOBOCAN estimates, approximately 529,000 women worldwide were diagnosed with invasive cervical cancer, and more than half of these patients died from their disease in 2008 [2] . Cervical carcinoma development begins with the infection of the cervical epithelium by high-risk human papillomaviruses (hr-HPVs) [3] [4] [5] . Although cervical cancer can be detected in its early stages by HPV testing and Papanicolaou (Pap) smear screening and successfully eradicated through surgery, curative treatments do not yet exist for advanced, recurrent or metastatic disease [6] [7] [8] .
Tumor growth and metastasis are driven by a small population of cancer stem cells (CSCs) [9] . The first extensive documentation of CSCs came from leukemia, in which only a small subset of cancer cells were shown to be capable of transferring the disease to non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice [10] . This concept was then extended to solid tumors. Human breast cancers have been demonstrated to contain a population of cells with stem cell properties that display surface marker expression of CD44
- [11] . Subsequently, CSCs have been identified and prospectively isolated using surface markers from a variety of malignancies, including brain tumors [12] , melanoma [13] , multiple myeloma [14] , prostate cancer [15] , colon cancer [16, 17] , head and neck squamous cell carcinoma [18, 19] and pancreatic adenocarcinoma [20] . Due to the instability and scarcity of surface markers in solid tumors, other methodological strategies have been widely explored to identify and isolate CSCs, including side population phenotype, sphere formation and aldehyde dehydrogenase (ALDH) activity assay [21] .
ALDH is a group of intracellular enzymes that oxidize aldehydes (thereby serving a detoxifying role) and convert retinol to retinoic acid, which mediates control over differentiation pathways [22, 23] . ALDH is highly expressed in hematopoietic stem cells and provides protection against the alkylating agent cyclophosphamide [24] [25] [26] [27] . Increasing evidence has suggested that ALDH activity can be used either alone or in combination with cell surface markers to identify CSCs in hematologic malignancies [28] and a steadily increasing number of solid tumors, including those of the breast [29] , colon [30] [31] [32] , bladder [33] , prostate [34, 35] , lung [36] , pancreas [37] , head and neck [38] , endometrium [39] , ovary [40] and melanoma [41] . Previous studies have shown that ALDH1 is expressed in cervical cancer cell lines and primary cervical cancer tissues [42] [43] [44] . However, the ability to isolate and identify cervical cancer stem cells (CCSCs) by ALDH activity has not yet been reported.
To verify whether cells with high ALDH activity are CCSCs, fluorescence activated cell sorting (FACS) and standard functional assays were used in the present study to analyze the cellular properties of ALDH high and ALDH low cells isolated from 4 human cervical cancer cell lines and 5 primary cervical cancers. The results indicated that a subpopulation of human cervical cancer cells with high ALDH activity possess enhanced selfrenewal capacities, differentiation potential and increased tumorigenicity, indicating that high ALDH activity may represent a marker of CSCs in cervical cancer.
RESULTS
ALDH expression and activity in human cervical tissue specimens and cervical cancer cell lines ALDH1 expression was evaluated in normal and cancerous cervical tissues ( Figure 1A ). Notable differences were observed in the expression patterns of ALDH1 in the basal cells of normal human cervical tissues; these patterns were classified into 4 types: (1) (Figure 1Aa-1Ad) . Most of these ALDH1-positive cells in the normal cervical stroma are likely CD45-positive leukocytes, which have also been found in the stroma of normal breast tissues by Dr. Deng et al. [45] .
ALDH1-positive cells were also found in all 53 cervical cancer tissues. Similar to ALDH1 expression in the normal cervical tissues, the expression patterns of ALDH1 in the cervical cancer tissues could be classified into 3 types: (1) Dot-scattered ALDH1 expression ( The ALDEFLUOR kit was used to test the ALDH enzymatic activity in the cervical cancer cell lines. Cells were labeled with activated ALDEFLUOR reagent in the presence or absence of the ALDH inhibitor, DEAB. A drop of ALDEFLUOR-labeled cells was smeared and examined by fluorescence microscopy. Fluorescent and phase contrast images were acquired and merged. As shown in Figure 1B, Figure 2B ). To exclude the effects of cell aggregation, which can occur in low density cultures, cells were cultured at a density of a single cell/ well. The ALDH high cells from SiHa, C33A, CaSki and HT-3 cells generated tumorspheres with an efficiency of 32.8%, 24.5%, 26.6% and 38.5%, whereas the ALDH low cells generated tumorspheres with an efficiency of 2.6%, 1.6%, 2.6% and 4.7%, respectively ( Figure 2C ). These data indicated that the ALDH high cervical cancer cells have greater self-renewal capacity than the ALDH low cells.
ALDH high cervical cancer cells have enhanced tumorigenic capacity in vivo
One of the most important characteristics of CSCs is their powerful ability to form tumors. To determine whether the ALDH high cells have a greater capacity to form tumors, the ALDH high and ALDH low cell populations were sorted from 4 cervical cancer cell lines, and limiting dilutions of the cells were subcutaneously injected into NOD/SCID mice. The tumor latency, tumor incidence and tumor volume were then monitored.
Firstly, tumor volume was monitored twice a week, Tumor latency was monitored after injection of sorted cells into the NOD/SCID mice and was defined by the period of time during which the mice remained tumor-free ( Figure 3B Figure 4A) . Similarly, 57.2% of the ALDH high C33A cells ( Figure 4B ), 72.1% of the ALDH high CaSki cells ( Figure 4C ) and 75.9% of the ALDH high HT3cells ( Figure 4D ) generated ALDH low cells. However, 98.52% of the ALDH low C33A cells ( Figure 4B ), 99.45% of the ALDH low CaSki cells ( Figure 4C ) and 99.86% of the ALDH low HT-3 cells ( Figure 4D) 
ALDH high cells are more resistant to cisplatin than ALDHlow cells
The resistance of CSCs to current chemotherapeutics is thought to be responsible for cancer recurrence and metastasis [46] . Because cisplatin is one of the most commonly used chemotherapeutic drugs in the treatment of cervical cancer, we tested the effects of cisplatin on ALDH high and ALDH low cervical cancer cells. After 
ALDH high cells express high levels of stem cellassociated markers
Stem cell-related transcription factors are important for maintaining the self-renewal of embryonic stem cells. To clarify whether the ALDH high cervical cancer cells express stem cell-related transcription factors, western blot analysis was performed to assess the expression of OCT4, NANOG, KLF4 and BMI1 in ALDH high and ALDH low cells. ALDH high C33A and HT-3 cells were found to express higher levels of OCT4, NANOG, KLF4 and BMI1 than ALDH low cells ( Figure 6A ). IHC analysis was also performed on the tumorspheres formed by the ALDH high and ALDH low SiHa cells to evaluate the expression of stem cell-associated markers ( Figure 6B ). Similar to the western blot analysis, the stem cell-associated transcription factors OCT4, NANOG, KLF4 and BMI1 were detected in the tumorspheres formed by the ALDH high SiHa cells but not the ALDH low SiHa cells. These data indicate that ALDH high cervical cancer cells display a nuclear stemness signature.
ALDH high cells from primary cervical cancers possess CSC characteristics
Our data suggest that ALDH high cells from cervical cancer cell lines display characteristics of CSCs. However, whether ALDH high cells derived from primary cervical cancers possess the same characteristics remained unknown. To address this question, primary cervical cancer tissues were processed into single cell suspensions and injected subcutaneously into NOD/SCID mice to create tumor xenografts. Only 5 out of 28 primary cervical cancer specimens were successfully serially transplanted for 5 generations; the estimated engraftment rate was 18%. The generated xenografts were resected and dissociated into single cell suspensions. Cells were plated in 24-well plates at a density of 10 3 cells/well and cultured for tumorsphere formation. All tumorspheres generated from the same cervical cancer tissue were collected, digested into single cell suspensions, labeled with the ALDEFLUOR kit, analyzed and sorted by FACS.
A subpopulation of ALDH high cells (11-23%) was detected in all 5 of the primary tumors tested ( Figure  7A ). The 10% of the cell population with the highest and the lowest ALDH activity were sorted as the ALDH high and the ALDH low cells, respectively, for the subsequent experiments. As shown in Figure 7B , the ALDH high , but not the ALDH low , primary cervical cancer cells were capable of generating tumorspheres in suspension culture. ALDH high cells formed tumorspheres with a frequency of approximately 10% in 3 consecutive passages ( Figure 7C ), while ALDH low cells did not generate tumorspheres (but did generate some cell aggregates). These data suggest that the ALDH high primary cervical cancer cells have the ability to self-renew.
To study the tumor formation capacity of the ALDH high and the ALDH low primary cervical cancer cells, 10 6 , 10 5 , 10 4 or 10 3 cells were subcutaneously injected into NOD/SCID mice, and the mice were monitored for tumor growth for 20 weeks. As summarized in Table 2 , the ALDH high primary cervical cancer cells exhibited enhanced tumorigenicity compared with the ALDH low cells. Among the 5 primary tumor samples, the tumor-initiating frequency of the ALDH high cells was as high as 6-200 times that of the ALDH low cells (Table 2 ). Furthermore, the 
DISCUSSION

Several approaches have been utilized to identify
CSCs from various human malignancies, including cell surface markers, side population phenotype, spheres formation and ALDH activity assays [21] . ALDH activity (measured using the ALDEFLUOR assay) was first used to isolate leukemia stem cells [28] . Subsequently, ALDH activity has been successfully used as a CSC marker for many solid tumors, including breast [29] , colon [30, 31] , bladder [33] , prostate [34], lung [36] , head and neck [38] , endometrium [39] , ovary [40] and thyroid [47] . Therefore, ALDH activity may have potential as a promising universal marker for the identification and isolation of stem cells from various solid tumors. However, previous reports have not indicated whether ALDH activity can also be used as a CSC marker in cervical cancer.
In the present study, the ALDH high cells isolated from 4 cervical cancer cell lines and 5 primary cervical cancer xenografts were demonstrated to fulfill the functional criteria for CSCs. Firstly, using the tumorsphere formation assay, ALDH high cervical cancer cells were found to have self-renewal capacity. ALDH high cells formed significantly more tumorspheres in both single cell culture and low density cell culture than ALDH low cells. Furthermore, ALDH high cells formed more tumorspheres in single cell culture than in low density cell culture ( Figure 2B and 2C) . Similar results have been reported for mammospheres, and cell aggregation in the low density cell cultures might contribute to the decreased formation of tumorspheres [29] . Secondly, ALDH high cervical cancer cells could differentiate and reconstitute the cellular hierarchy in vitro and in vivo. After 2 weeks of culture in medium containing FBS, ALDH high cells differentiated into many ALDH low cells, while ALDH low cells generated few ALDH high cells and predominantly maintained the ALDH low phenotype (Figure 4A-4D) . The ALDH1-positive population could be detected in all of the tumor xenograft tissues formed by the ALDH high cells, but no ALDH1-positive cells were found in the tumors formed by the ALDH low cells ( Figure  4E ). Therefore, only the ALDH high cells, not the ALDH low cells, could differentiate and re-establish the cellular hierarchy in vitro and in vivo. Thirdly, ALDH high cervical cancer cells had tumor initiating capacity in vivo. The tumors formed by the ALDH high cells were larger and grew faster than those derived from the ALDH low cells ( Figure  3A) . A shorter tumor-free period and a lower tumor-free rate were observed in mice injected with the ALDH high cells than in mice injected with ALDH low cells ( Figure 3B ). The tumor-initiating frequency of the ALDH high cells was significantly higher than that of the ALDH low cells ( Table  1) . Taken together, these data indicate that the ALDH high cells are indeed CSCs in cervical cancer, similar to the results of previous ALDH studies in other solid tumors [29, 30, 33, 34, 36, 41] .
ALDH expression and activity has been reported to be significantly higher in taxane-and platinum-resistant ovarian cancer cell lines [40] . Rahadiani et al. have reported that ALDH high endometrioid adenocarcinoma cells are more resistant to cisplatin treatment than ALDH low cells [39] . In this study, the ALDH high cells were more resistant to cisplatin treatment than the ALDH low cells (Figure 5 ), suggesting that ALDH high CCSCs exhibit chemoresistance similar to the CSCs found in other solid tumors [39, 48] . Surprisingly, the viability of the ALDH high C33A cells was significantly enhanced following exposure to cisplatin ( Figure 5B and C) . We attribute this to stimulated proliferation or enhanced activity of succinic acid dehydrogenase, which is the enzyme activity measured by the MTT assay. Further experiments are necessary to clarify the mechanisms that underlie the enhanced viability of the ALDH high C33A cells. The direct isolation of CSCs from uncultured human primary colon [30] and prostate [34] cancer cells and sorting based on ALDH activity has been reported. ALDH high CSCs in breast cancer [29] and pancreatic cancer [37] have been successfully isolated from primary cancer xenografts established in mice. In the present study, uncultured primary cervical cancer cells were first used to investigate the tumorigenicity of the ALDH high and the ALDH low cells. Unfortunately, neither the ALDH high nor the ALDH low cells from primary cervical cancer resulted in tumors in NOD/SCID mice, similar as the report about ovarian cancer [40] . Three possibilities may contribute to the failure of CSC isolation directly from primary uncultured cervical cancer cells: (1) ALDH-positive noncancerous cells, including white blood cells, stromal cells or normal stem cells, were abundant in the primary cancer tissues and contaminated the cancerous cells during tumor formation; (2) all primary cervical cancer tissues obtained from surgery are likely below the clinical stage of II a, and most of these cancerous cells may be too fragile to be sorted; or (3) the cells may be not resilient enough to form tumors in NOD/SCID mice. In the present study, CSCs were isolated from 5 generations of cervical cancer serially xenografted in NOD/SCID mice but not from uncultured primary cervical cancer cells. The following 3 possibilities may explain this phenomenon: (1) After more than 5 serial xenograft generations in NOD/SCID mice, primary cervical cancer cells acquired the capacity to form tumors; this idea is consistent with the notion that cancer cells can acquire enhanced tumorigenicity through serial transplantation in mice. (2) In this study, only 5 of the 28 cases of primary cervical cancer (approximately 18%) could successfully be serially transplanted for more than 5 generations in mice, indicating that the cancer cells in most primary cancer tissues were too fragile to form tumors in NOD/SCID mice. (3) The cells used for the tumor formation assay were isolated from tumorspheres, which decreases the likelihood of contamination with ALDH-positive non-cancerous cells from the primary cancer tissues.
ALDH1 has been reported to be a marker for normal mammary stem cells [29] . In this study, ALDH1 expression was found in the basal cells of normal cervical tissue ( Figure 1A, upper panel) . The basal cells were recognized to contain cervical stem cells. Therefore, ALDH1 may be a marker of normal cervical stem cells. Further experiments should be designed to isolate and test the ALDH1-positive cervical basal cells to verify whether ALDH1 can be used as a marker of normal cervical stem cells.
In summary, this report is the first to describe the use of high ALDH activity to isolate CSCs from cervical cancer cell lines and primary cervical cancer cells. These ALDH high cervical cancer cells possess the ability to selfrenew and differentiate and have enhanced tumorigenicity. Additionally, these cells exhibit chemoresistance and express high levels of stem cell-related transcription factors. Based on this study, ALDH activity may be used as a cytoplasmic marker for CCSCs, and a target to explore novel strategies for diagnosis, prognosis and therapy.
METHODS
Ethics Statement
Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines and has been approved by the review board of the First Affiliated Hospital of Xi'an Jiaotong University.
Cell lines and culture conditions
The human cervical cancer cell lines SiHa, C33A, CaSki and HT-3 were obtained from the American Type Culture Collection (ATCC; Manassas, VA). SiHa and C33A cells were cultured in Dulbecco's Modified Eagle Medium-high glucose (DMEM; Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA). CaSki and HT-3 cells were cultured in RPMI-1640 (Sigma-Aldrich) and McCoy's 5A medium (Sigma-Aldrich), respectively, supplemented with 10% FBS. All cell lines were maintained at 37°C in an atmosphere containing 5% carbon dioxide.
Human tissue specimens, primary cervical cancer tissue processing and xenograft lines
A total of 17 normal cervical tissues and 53 cervical cancer tissues were obtained from the First Affiliated Hospital of Xi'an Jiaotong University. The procedures followed approved medical ethics practices, and the patients provided their informed consent before the specimens were collected. Fresh cervical cancer tissues were obtained from 28 patients after radical hysterectomy and used for xenograft experiments. Single cell suspension was generated by mincing and digesting the tissue with 100 U/mL collagenase IV (GIBCO, Grand Island, NY) in basal medium at 37°C overnight. Xenograft lines were established by subcutaneous implantation of the primary cervical cancer cells in 6-to 8-week old NOD/SCID mice (Charles River Laboratories, Wilmington, MA). Once established, the solid tumor xenografts were serially passaged using the same technique.
Immunohistochemistry (IHC)
Formalin-fixed and paraffin-embedded tissue specimens were sliced into 4 mm sections, which were then deparaffinized and hydrated. An endogenous antigen retrieval procedure was performed using citric acid buffer (10 mmol/L citrate buffer, pH 6.0). The slides were incubated with a mouse monoclonal antibody raised against human ALDH1 (BD Biosciences, Franklin Lakes, NJ) or Ki67 (Santa Cruz, CA) overnight at 4°C, then with secondary antibodies for 30 min at room temperature, followed by diaminobenzidine development. All slides were examined under an Olympus-CX31 microscope (Olympus, Tokyo, Japan).
Flow cytometry analysis and FACS isolation of cells
The ALDH enzymatic activity of the cells was measured using the ALDEFLUOR kit (Stem Cell Technologies, Vancouver, BC, Canada), according to the manufacturer's instructions. The brightly fluorescent ALDH-expressing cells were detected using a FACSCalibur or FACSAria flow cytometer (BD Biosciences). As a negative control, cells were stained under identical conditions after treatment with the specific ALDH inhibitor diethylaminobenzaldehyde (DEAB). The data were analyzed using FlowJo software (Tree Star Inc., Ashland, USA). For FACS, the cells were labeled using the ALDEFLUOR kit and sorted using a FACSAria cell sorter (BD Biosciences). www.impactjournals.com/oncotarget Tumorsphere culture Cells were maintained in stem cell media consisting of DMEM/F12 basal media, N2 and B27 supplements (Invitrogen), 20 ng/mL human recombinant epidermal growth factor (EGF) and 20 ng/mL basic fibroblastic growth factor (bFGF; PeproTech Inc., Rocky Hill, NJ). For the tumorsphere formation assay, cells were plated at a density of 200 cells/well in 24-well ultra-low attachment plates or at a density of 1 cell/well in 96-well plates and maintained in stem cell medium. Tumorspheres that arose within 2 weeks were recorded. For serial tumorsphere formation assays, the spheres were harvested, disaggregated with 0.25% trypsin/EDTA, filtered through a 40 µm mesh and re-plated as described above. For each cell type, triplicate samples were done and the spheres were counted by two individuals in a blind fashion.
Western blot
Cells were lysed in a lysis buffer (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 2 mM EDTA; 1% NP-40; and 0.1% sodium dodecyl sulfate) that contained a protease inhibitor cocktail (Complete Mini; Roche Diagnostics, Branchburg, NJ). The membranes were incubated with antibodies raised against ALDH1 (BD Biosciences), BMI1 (Millipore, Billerica, Mass), OCT4 (Santa Cruz), KLF4 (Santa Cruz) and GAPDH (Santa Cruz) at 4°C overnight, followed by a secondary incubation with horseradish peroxidase-conjugated immunoglobulin G (IgG; Thermo Fisher Scientific, New York, NY). The membranes were briefly incubated with an enhanced chemiluminescence reagent (Millipore, Billerica, Mass), then visualized on x-ray films.
Drug resistance and MTT assay
For drug resistance assays, cells were plated in 96-well plates at a density of 10 4 cells/well and allowed to recover overnight before initiating drug treatments. The cells were exposed to various concentrations of cisplatin (0, 3, 6, 12, 24, or 48 µg/mL for SiHa and C33A cells or 0, 0.5, 1, 2, 4, or 8µg/mL for CaSki and HT-3 cells) for 24 h, and the cell viability was measured. In separate experiments, the cells were exposed to a constant concentration of cisplatin (3 µg/mL for SiHa and C33A cells or 1 µg/mL for CaSki and HT-3 cells) for 24, 48 or 72 h, and the cell viability was measured.
Cell viability was assessed using a 3-(4, 5-Dimethyl-1, 3-thiazol-2-yl)-2, 5-diphenyl-2H-tetrazol-3-ium bromide (MTT; Sigma-Aldrich) assay. Following the manufacturer's instructions, 20 µL of MTT solution were added to 200 µL of the culture media. The plates were then incubated for 4 h at 37°C, and the optical density was measured at 490 nm.
In vivo tumor formation assays
The ALDH high and ALDH low cells were sorted, re-suspended in 200 µL of 1:1 PBS/Matrigel (BD Biosciences) and injected subcutaneously into the flanks of 6-to 8-wk old female NOD/SCID mice; the left flank of the mouse received the ALDH high cells, whereas the right flank received the ALDH low cells. Engrafted mice were inspected twice per week by visual observation and palpation for the appearance of tumors. The tumor volume (V) was determined from the length (a) and the width (b) of the tumor, using the formula V=ab 2 /2 [49] . A portion of each tumor tissue was fixed in 10% formaldehyde and embedded in paraffin for IHC analysis. The frequency of tumorigenic cells (estimated with upper-lower limits) was calculated by limiting-dilution analysis [50] .
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5.01 software (La Jolla, CA, USA). In comparisons of 2 groups, Student's t-test was used to determine the statistical significance. To examine differences among 3 groups, an ANOVA analysis was performed. KaplanMeier survival analysis was performed and survival curve comparison analyses were performed using the log-rank (Mantel-Cox) test. P values of ≤0.05 were regarded as statistically significant.
